Hope Pharmaceuticals Files Supplemental New Drug Application to the Food and Drug Administration for Sodium Thiosulfate Injection

SCOTTSDALE, Ariz., June 07, 2018 (GLOBE NEWSWIRE) -- Hope Pharmaceuticals today announced that the company filed a Supplemental New Drug Application to the United States Food and Drug Administration (FDA) for the use of Sodium Thiosulfate Injection to prevent a potential complication associated with the administration of a chemotherapeutic agent. 

Hope Pharmaceuticals’ Sodium Thiosulfate Injection has already been approved by the FDA as an antidote for acute cyanide poisoning that is judged to be life-threatening and is currently distributed in the United States in individually-packaged 50 mL vials. 

Additional information about Sodium Thiosulfate Injection is available online at www.thiosulfate.info.

Hope Pharmaceuticals is a privately owned company located in Scottsdale, Arizona. 

Media Inquiries:                     
Craig Sherman, M.D. 
(480) 607-1970 or questions@hopepharm.com 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/46d06ce3-2c6d-4331-b241-780a196d92c5